Kiniksa Pharmaceuticals's total assets for Q2 2025 were $661.15M, an increase of 10.32% from the previous quarter. KNSA total liabilities were $166.14M for the fiscal quarter, a 17.14% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.